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Sir,
We read with great interest the study by Sideras et al (2015) that
combines tissue microarrays (TMA) and immunohistochemistry to
investigate the expression pattern of 15 antigens belonging to different
categories, including cancer testis antigens (CTAs) and oncofetal proteins
in primary hepatocellular carcinoma (HCC). Because current therapies
for HCC are far from ideal (Ilan, 2014) and immunotherapy has been
proposed as a potential therapeutic option, the authors aimed at
identifying a panel of relevant tumour antigens with broad expression in
a Western European population of HCC patients and specific expression
in the tumour tissue (Sideras et al, 2015). Cancer testis antigens represent
a family of 4200 proteins selectively expressed in malignant cells, but
not in their natural counterpart except for human germ cells (Simpson
et al, 2005; Gjerstorff et al, 2015; Grizzi et al, 2015). Among the different
types of tumour antigens, CTAs identified highly promising therapeutic
targets (Gjerstorff et al, 2015). In contrast to previous studies (Xu et al,
2012; Liang et al, 2013; Xia et al, 2013; Wang et al, 2015), Sideras et al
(2015) found a low (o10% of patients) prevalence of expression of
MAGE-A3/4, NY-ESO-1, MAGE-A1 and MAGE-A10. Moreover, a low
(o10% of patients) prevalence of expression of the foetal specific
glycoprotein alpha-fetoprotein (AFP) was found. Although its serum
level falls rapidly after birth and its synthesis in adult life is repressed,
470% of HCC-affected patients have usually a high serum concentration
of AFP. Today, AFP and ultrasonography are the main tests for HCC
surveillance in clinical practice, and in the interim, using ultrasono-
graphy and AFP in combination may be the best strategy to optimise
early HCC detection (Mehta and Singal, 2015). Sideras et al (2015) stated
that the observed prevalence of expression of CTAs and oncofetal
antigens was generally lower because previous studies have been
conducted in East Asia where hepatitis B virus infection is the prevalent
cause of HCC and the majority of HCC patients have liver cirrhosis.
Furthermore, previous investigators used RT–PCR measuring mRNA
expression, whereas they evaluated protein expression by immunohis-
tochemistry. Here, we would like to discuss additional points underlying
these discrepancies and that impact on the CTAs as immunotherapeutic
targets. In an effort to accelerate translation of new developments in
basic immunology into cancer patients, representatives from eight
immunotherapy organisations representing Europe, Japan, China and
North America convened an ‘Immunotherapy Summit’ at the 24th
Annual Meeting of the International Society for Biological Therapy of
Cancer (now called Society for Immunotherapy of Cancer, SITC). One of
the concepts raised by SITC and defined as critical was the need to
identify hurdles that impede effective translation of cancer immunother-
apy (Fox et al, 2011). The critical hurdles highlighted have been grouped
into nine general themes. Among these have been identified the
‘complexity of cancer’, its ‘heterogeneity’ and ‘immune escape’ (Fox
et al, 2011). Hepatocellular carcinoma originates and progresses
throughout a dynamic process involving different ‘driven alterations’
that ultimately lead to the malignant transformation of hepatocytes.
Malignant transformation may occur regardless of the aetiologic agent
through a pathway of increased liver cell turnover, induced by chronic
liver injury and regeneration in a context of inflammation, immune
response and oxidative DNA damage (Li and Wang, 2015). Hepatocel-
lular carcinoma is a heterogeneous disease in ‘space’ and in ‘time’. The
term ‘heterogeneity’ defines the presence of cell clones, within a tumoral
mass, with different genetic aberrations that mediate divergent biology
defining the natural history of that particular tumour, that is, one clone
does not represent the entirety of the tumour cell population. This
variability is what ultimately determines the evolutionary progression of
neoplastic disease and its response to therapy (Luo et al, 2009). Singular
cells respond differently to the same stimulus, with some not responding
at all (Floor et al, 2012; Almendro et al, 2013). These considerations, in
conjunction with the complexity of ‘tumour–host’ interactions caused by
temporal changes in tumour phenotypes and an array of immune
mediators expressed in the tumour microenvironment, might explain the
limited reliability and applicability of current therapeutic strategies.
Sideras et al (2015) did not report fundamental hallmarks of cancer,
including ‘cancer complexity’, ‘tumour heterogeneity’ and ‘field cancer-
ization’, that is, the presence of abnormal tissue surrounding primary
cancerous lesions. These observations lead us to reflect on the
appropriateness of TMAs to state the CTAs and oncofetal proteins as
potential therapeutic targets. It is known that diagnostic accuracy of a
histological assay may be affected if the ‘target antigen’ is uniquely
present in a fraction of a tumour (Sottoriva et al, 2015). Tissue
microarray consists of small fractions of tissue inserted into a recipient
paraffin block such that a tissue section on a single glass slide can contain
numerous patient samples in a spatially structured pattern. Although the
study of whole-tissue sections for the evaluation of large tumour cohorts
is tedious and costly, the genome-wide network of intra-tumour
heterogeneity across multiple spatial and temporal scales, and patient-
specific patterns of cancer evolution limits the appropriateness of
investigating a small fraction of tissue, and is prone to controversial
results and consequences for treatment design (Chiriva-Internati et al,
2004). In addition, Sideras et al (2015) applied a scoring system, called
‘H-score’ obtained by multiplying the intensity score (range: 0–3) with
the level of % of positive cells, where 1p5%, 2¼ 5–25%, 3¼ 25–75% and
4 X75%. However, this approach generates equivalent ‘mathematical
products’, (i.e., condition 1: intensity¼ 1 multiplied with the level of % of
positive cells 2¼ 5–25% is the same product obtained multiplying
intensity¼ 2 with the level of % of positive cells 1p5%; condition 2:
intensity¼ 1 multiplied with the level of % of positive cells 3¼ 25–75% is
the same product obtained multiplying intensity¼ 3 with the level of %
of positive cells 1 o5%; condition 3: intensity¼ 1 multiplied with the
level of % of positive cells 4 X75% is the same product obtained
multiplying intensity¼ 2 with the level of % of positive cells 2¼ 5–25%;
condition 4: intensity¼ 2 multiplied with the level of % of positive cells
3¼ 25–75% is the same product obtained multiplying intensity¼ 3 with
the level of % of positive cells 2¼ 5–25%), although their biological
significance is completely different. In other words, these overlapping
‘scores’ subtend different impacts on the capacity of CTAs to elicit the
immune response and the heterogeneous behaviour of HCC. In
conclusion, to advance our knowledge in a currently widely debated
field of investigation such as that of immunotherapy and HCC, a clearer
distinction must be made between the exploration of CTA expression
pattern and their real application in human clinical trials. Because the
analysis of CTA expression is useful in identifying patients who are most
likely to benefit from immune intervention strategies, we need to adopt a
more adequate experimental approach and a change in our ‘mind’ from a
‘qualitative’ or ‘semi-quantitative’ to a more advanced ‘quantitative’
thinking.
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